220200-88-4

Usage

Uses

Used in Pharmaceutical Industry:
(2R,4R)-4-Methyl-2-trichloro-methyloxazolidin-5-one is used as a reagent in organic synthesis for the construction of chiral building blocks. Its enantiomers are particularly valuable for the selective synthesis of chiral compounds, which are essential in the development of pharmaceuticals that target specific biological receptors with high precision.
Used in Agrochemical Industry:
Similarly, in the agrochemical industry, (2R,4R)-4-Methyl-2-trichloro-methyloxazolidin-5-one serves as a reagent for the synthesis of chiral building blocks. This allows for the development of agrochemicals with enhanced selectivity and reduced environmental impact, as the desired enantiomer can be synthesized without producing unwanted isomers that may have adverse effects on non-target organisms.

InChI:InChI=1/C8H10Cl3NO2/c1-7-3-2-4-12(7)5(8(9,10)11)14-6(7)13/h5H,2-4H2,1H3/t5-,7+/m1/s1

Upstream product

• 118916-60-2 (2R,5S)-2-trichloromethyl-1-aza-3-oxabicyclo[3.3.0]octan-4-one 
• 74-88-4 methyl iodide 
• 74-83-9 methyl bromide 
• 147-85-3 L-proline 

Downstream Products

• 220060-08-2 methyl (S)-2-methylpyrrolidine-2-carboxylate monohydrochloride 
• 42856-71-3 (S)-2-methylpyrrolidine-2-carboxylic acid 
• 123053-48-5 (S)-2-methylpyrrolidine-2-carboxylic acid hydrochloride 
• 869001-86-5 N-benzyloxycarbonyl-glycyl-L-2-methylproline 
• 847952-40-3 (S)-methyl 1-(2-(((benzyloxy)carbonyl)amino)acetyl)-2-methylpyrrolidine-2-carboxylate 
• 869001-94-5 dibenzyl N-benzyloxycarbonyl-glycyl-L-2-methylprolyl-L-glutamate 
• 853400-76-7 glycyl-L-2-methylprolyl-L-glutamic acid 
• 847952-36-7 (8aS)-8a-methylhexahydropyrrolo[1,2-a]pyrazine-1,4-dione 

Relevant academic research and scientific papers

BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME

Embodiments of this invention provide compounds, compositions, methods, and uses for therapeutic diketopiperazines, including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat Pitt Hopkins Syndrome and symptoms thereof, as well a

METHOD FOR PREPARATION OF ALPHA-METHYL-L-PROLINE

The invention discloses a method for preparation of alpha-methyl-L-proline starting from proline and comprising three steps, first a conversion with chloral, then a conversion with methyl bromide and then a conversion with aqueous HCl.

A Designed Approach to Enantiodivergent Enamine Catalysis

The rational design and implementation of enantiodivergent enamine catalysis is reported. A simple secondary amine catalyst, 2-methyl-l-proline, and its tetrabutylammonium salt function as an enantiodivergent catalyst pair delivering the enantiomers of α-functionalized aldehyde products in excellent enantioselectivities. This novel concept of designed enantiodivergence is applied to the enantioselective α-amination, aldol, and α-aminoxylation/α-hydroxyamination reactions of aldehydes.

Spatial Configuration and Three-Dimensional Conformation Directed Design, Synthesis, Antiviral Activity, and Structure-Activity Relationships of Phenanthroindolizidine Analogues

Our recent investigation on the antiviral activities against tobacco mosaic virus (TMV) of phenanthroindolizidine alkaloid analogues preliminarily revealed that the basic skeleton and substitution pattern at the C13a position of the molecule, which are cl

NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING AUTISM SPECTRUM DISORDERS AND NEURODEVELOPMENTAL DISORDERS

Embodiments of this invention provide compositions and methods for therapeutic use of diketopiperazines including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat symptoms of Autism Spectrum Disorders and Neurodevelopmental Diso

Complementary stereochemical outcomes in proline-based self-regenerations of stereocenters

Stereoselective alkylations of proline-based amino amides are described, where high levels of either a cis or trans configuration can be attained simply by the choice of the aminal group. Isobutryaldehyde-derived aminals provide the cis configuration, whi

The first enantioselective approach to 13a-methyl-14- hydroxyphenanthroindolizidine alkaloids - Synthetic studies towards hypoestestatin 2

The first enantioselective approach to 13a-methyl-14- hydroxyphenanthroindolizidine alkaloids was achieved in six linear steps from phenanthryl alcohol and features a highly substrate-dependent Parham cycloacylation and Seebach's enantioselective alkylation as the key steps. The route is concise, protecting-group free, provides access to all stereoisomers, and works on a gram scale. In addition to the putative structure of hypoestestatin 2, the other three stereoisomers and two structurally related analogues were synthesized, none of which shows identical NMR spectra to those reported for natural hypoestestatin 2, which indicates that further structure revision is required. By using Seebach's stereoselective alkylation and Parham cyclization as key steps, the first strategy for the synthesis of 14-hydroxy-13a-methylphenanthroindolizidine alkaloids was developed. The route is practical (six steps in 30 % overall yield) and adaptable for all stereoisomers. In addition, we demonstrate for the first time that the structure of hypoestestatin 2 was misassigned.

CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS

Embodiments of this invention provide methods for therapeutic use of cyclic G-2-Allyl Proline to treat cognitive disorders as well as manufacture of medicaments including tablets, capsules, injectable solutions that are useful for treatment of such condit

ANALOGS OF GLYCYL-PROLYL-GLUTAMATE

Embodiments of this invention include novel analogs of Glycyl-Prolyl-Glutamate (GPE) and compositions containing such analogs of GPE. Of these, certain analogs have modified proline residues. Other embodiments of this invention include uses of analogs of GPE to protect neural cells from degeneration and/or death in response to injury or disease. Disorders treatable with compounds and compositions of this invention include hypoxia/ischemia, toxic injury, and chronic neurodegenerative disorders including Parkinson''s disease.

Synthesis of proline-modified analogues of the neuroprotective agent glycyl-L-prolyl-glutamic acid (GPE)

The synthesis of ten proline-modified analogues of the neuroprotective tripeptide GPE is described. Five of the analogues incorporate a proline residue with a hydrophobic group at C-2 and two further analogues have this side chain locked into a spirolactam ring system. The pyrrolidine ring was also modified by replacing the γ-CH2 group with sulfur and/or incorporation of two methyl groups at C-5.